Institutional Confidence and Analyst Optimism Counter Insider Selling at Boston Scientific

Despite a notable series of stock sales by the company’s own executives, major institutional investors and market analysts continue to express strong confidence in the medical device manufacturer’s prospects. Recent activity highlights both a substantial purchase by an investment firm and sustained bullish price targets from research desks.

Market experts remain firmly positive on the equity. The prevailing consensus recommendation is a “Buy,” supported by an average price target of $123.77. Some research compilations are even more optimistic, citing an average target of $126.48. Based on a recent closing price of $99.02, this represents a potential upside of over 24%. This confidence is largely fueled by the company’s robust Read more...